Covered recipient · General Payments record
SOHA MOUSA
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2018–2024
$9,802.37
- Reported across 462 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $810.00 | 1 |
| Food and Beverage | $580.91 | 32 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $810.00 | 1 |
| ABBVIE INC. | $235.44 | 19 |
| GlaxoSmithKline, LLC. | $155.80 | 4 |
| Acerta Pharma LLC | $49.74 | 2 |
| PFIZER INC. | $41.33 | 2 |
| UCB, Inc. | $35.98 | 2 |
| Amgen Inc. | $33.70 | 1 |
| Aurinia Pharma U.S., Inc. | $15.00 | 1 |
| E.R. Squibb & Sons, L.L.C. | $13.92 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $9.92 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074647 | CMS |
| ABBVIE INC. | $12.35 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074649 | CMS |
| ABBVIE INC. | $10.46 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074651 | CMS |
| ABBVIE INC. | $10.54 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074653 | CMS |
| ABBVIE INC. | $20.11 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074655 | CMS |
| ABBVIE INC. | $2.92 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074657 | CMS |
| ABBVIE INC. | $12.75 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074659 | CMS |
| ABBVIE INC. | $9.45 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074661 | CMS |
| ABBVIE INC. | $9.93 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074663 | CMS |
| ABBVIE INC. | $8.84 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074665 | CMS |
| ABBVIE INC. | $14.77 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074667 | CMS |
| ABBVIE INC. | $7.73 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074669 | CMS |
| ABBVIE INC. | $9.38 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074671 | CMS |
| ABBVIE INC. | $10.85 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074673 | CMS |
| ABBVIE INC. | $14.34 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074675 | CMS |
| ABBVIE INC. | $25.16 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074677 | CMS |
| ABBVIE INC. | $15.90 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074679 | CMS |
| ABBVIE INC. | $24.05 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074681 | CMS |
| ABBVIE INC. | $5.99 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105074683 | CMS |
| Amgen Inc. | $33.70 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115948839 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.97 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105495509 | CMS |
| AstraZeneca Pharmaceuticals LP | $29.77 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105507298 | CMS |
| Aurinia Pharma U.S., Inc. | $15.00 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150687923 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.92 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101758826 | CMS |
| GlaxoSmithKline, LLC. | $18.16 | 08/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115848296 | CMS |
| GlaxoSmithKline, LLC. | $15.88 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116181283 | CMS |
| GlaxoSmithKline, LLC. | $105.55 | 10/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116584243 | CMS |
| GlaxoSmithKline, LLC. | $16.21 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116384668 | CMS |
| Janssen Biotech, Inc. | $810.00 | 01/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1078523332 | CMS |
| PFIZER INC. | $22.54 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131687847 | CMS |
| PFIZER INC. | $18.79 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131883012 | CMS |
| UCB, Inc. | $18.87 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143268640 | CMS |
| UCB, Inc. | $17.11 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143268644 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.